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Acute myeloid leukemia (AML) is a typically lethal molecularly heterogeneous disease, with
few broad-spectrum therapeutic targets. Unusually, most AML retain wild-type TP53,
encoding the pro-apoptotic tumor suppressor p53. MDM2 inhibitors (MDM2i), which acti-
vate wild-type p53, and BET inhibitors (BETi), targeting the BET-family co-activator BRD4,
both show encouraging pre-clinical activity, but limited clinical activity as single agents. Here,
we report enhanced toxicity of combined MDM2i and BETi towards AML cell lines, primary
human blasts and mouse models, resulting from BETi’s ability to evict an unexpected
repressive form of BRD4 from p53 target genes, and hence potentiate MDM2i-induced p53
activation. These results indicate that wild-type TP53 and a transcriptional repressor function
of BRD4 together represent a potential broad-spectrum synthetic therapeutic vulnerability
for AML.
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Despite numerous advances in the knowledge of themolecular landscape of Acute Myeloid Leukemia (AML),there remains an unmet need to improve clinical out-
comes; 5-year survival rates in 2019 for adults diagnosed with
AML remain below 30%1. AML is a genetically and epigenetically
heterogeneous disease, characterized by recurrent but diverse
chromosomal structural changes and genetic mutations asso-
ciated with functionally distinct sub-groups2,3. In addition to
disease heterogeneity between patients, marked sub-clonal het-
erogeneity has also been observed within individual AML
patients4. To date these disease features have posed a significant
obstacle to finding novel targeted agents with a broad therapeutic
reach.
One key unifying feature of AML, that could potentially be
exploited to benefit many patients, is that the majority of cases
exhibit wild-type TP532,3. In AML with wild-type TP53, the p53
tumour suppressor protein is commonly held functionally inert
through dysregulation of the ARF-MDM2/4 axis, culminating in
inactivation of p53 by its negative regulators, MDM2 and
MDM45. Drugs and small molecules have been developed that
can activate p53 in cells expressing the wild-type gene6, with the
goal of unleashing p53’s potent tumor suppressive functions.
Clinical grade MDM2 inhibitors (MDM2i) have been tested in
the clinic, for example RG7112 in hematological and solid
tumors, with some encouraging, but limited, responses6,7.
Nevertheless, in pre-clinical studies, MDM2i cooperated with
“standard-of-care” therapies, daunorubicin and cytarabine, to
eradicate AML8; and the BCL2 inhibitor (Venetoclax) and
MDM2i (Idasanutlin/RG7388 [a clinical grade RG7112 derivative
with improved potency, selectivity and bioavailability]9) are also
synthetic lethal in AML10. Other combination strategies have also
demonstrated the utility of targeting wild-type p53 in AML11.
Consistent with these studies, Andreeff et al have proposed that
use of MDM2i to activate p53 will likely realize more benefit in
combination therapies7.
Bromodomain-containing protein 4 (BRD4) is a member of the
bromodomain and extraterminal (BET) family proteins, char-
acterized by two N-terminal bromodomains and an extraterminal
domain12. BRD4 has been shown to play a role in the activation
of genes involved in cell growth - most notably c-MYC - through
binding to acetylated histones and transcription factors, to which
BRD4 then recruits transcriptional regulators, such as positive
transcription elongation factor b (P-TEFb) and Mediator com-
plex12. Although c-MYC translocations or mutations are not
common in AML, the activation of c-MYC by multiple up-stream
leukemic genetic aberrations has been recognized as a key hub in
driving leukemogenesis13. Pre-clinical data has demonstrated that
inhibition of BRD4 has efficacy across a range of AML sub-
types14–16. Indeed, BET inhibitors (BETi) have entered early
phase clinical trials for AML. However, despite promising pre-
clinical activity, their efficacy in treating AML as single agents has
been modest17–20, and as such it is likely that, like MDM2i, their
strength lies in rational combination therapies.
In sum, both MDM2i and BETi have been considered as
therapies for AML, but on their own have shown limited clinical
activity6,7,17–20. Given that both drugs can, in principle, target a
broad spectrum of AML molecular subtypes and the two drugs
have distinct modes of action, we set out to test the hypothesis
that the concomitant reactivation of p53 and inhibition of BET
family proteins, using MDM2i and BETi, could synergise to kill
AML cells. Here we present data showing superior efficacy of the
drug combination over the single agents in genetically hetero-
genous AML cell lines, primary AML samples, and two relevant
mouse models. We present mechanistic data demonstrating how
this efficacious drug combination co-operates to induce pro-
apoptotic p53 target genes.
Results
BETi enhance the killing of human AML cells by MDM2i in a
p53-dependent manner. Initial experiments to assess potential
synergy of the MDM2i and BETi combination were performed in
a panel of primary AML cells from 15 heterogeneous AML
patients. These patients had a median age of diagnosis of 60 years
(range 31 to 78 years). Based on their non-complex karyotype we
expect the majority to retain wild-type TP532, and this was
confirmed for the 4 samples for which DNA sequencing data was
available (Supplementary Fig. 1A). In these initial in vitro studies,
for BETi we used CPI203 (Constellation Pharmaceuticals), and
for MDM2i we used nutlin-3 (Sigma). CPI203 is a potent BETi
with an IC50 of 37 nM for inhibition of BRD421. Like other BETi,
CPI203 represses expression of oncoproteins, such as c-MYC21.
CPI203 is a pre-clinical tool compound version of CPI0610,
another Constellation BETi already being tested in human
AML22. Nutlin-3 is a potent inhibitor of the interaction between
p53 and its negative regulator MDM223, thereby activating p53 to
inhibit cell proliferation and tumorigenesis in models harboring
wild-type TP53. As an assessment of potential drug synergy, we
measured cell viability reflected in ATP levels (CellTitre-Glo,
Promega). Across all 15 patient samples, the combination of
CPI203 and nutlin-3 was significantly more efficacious than
either drug alone (Fig. 1a). To more quantitatively assess drug
interactions, we calculated the coefficient of drug interaction
(CDI) for each sample; CDI < 1, =1 or >1 indicates that the drugs
are synergistic, additive or antagonistic, respectively. The majority
of the samples showed a trend towards greater than additive
killing by the combination (x axis < 1), compared to the single
drugs (Fig. 1b). For 4 of the samples, this synergistic interaction
was determined to be significant (p < 0.05). Due to limited sample
availability, TP53 mutation status could only be determined by
DNA sequencing for 4 of the human patient samples. Of these, all
retained wild-type TP53 and 3 of them showed at least a trend
towards synergy. These results in primary patient samples point
to enhanced toxicity of the BETi and MDM2i combination,
compared to single agents, against a substantial proportion of
primary human AML.
To extend these results obtained in primary AML blasts and to
be able to perform more rigorous mechanistic analyses, we tested
synergy between nutlin-3 and CPI203 in a panel of 3 human
AML cell lines expressing wild-type p53 (OCI-AML3, MOLM13,
MV411). To begin to assess the p53 dependence of any effect, we
also tested 3 cell lines with mutant TP53 (THP1, KG1a, Kasumi1).
Irrespective of TP53 status, these AML cell lines reflect diverse
AML subtypes. For example, OCI-AML3 harbor DNMT3A and
NPM1 mutations, MOLM13 and MV411 both contain mutant
FLT3-ITD, MOLM13 expresses an MLL-AF9 fusion oncoprotein,
while MV411 expresses the MLL-AF4 fusion oncoprotein (ref. 24
and ATCC). We confirmed initially that the drugs engaged their
molecular targets, reflected in upregulation of p53 and CDKN1A
(p21) by nutlin-3, and down regulation of c-MYC by CPI203
(irrespective of TP53 status) (Fig. 1c, d). To compare the effects of
the single drugs and combination on viability of these 6 cell lines,
we used resazurin (a metabolic viability sensor) across a range of
fixed drug dose ratios, enabling drug interaction to be
quantitatively assessed by the combination index (CI) method,
where CI < 1 is generally considered as synergy25. Consistent with
previous studies in OCI-AML3 cells26, the drug combination
demonstrated apparent synergy in wild-type TP53 cell lines
(Fig. 1e–g and Supplementary Fig. 1B–D). In the TP53 wild-type
OCI-AML3 cell line, CPI203 and nutlin-3 were designated
synergistic from CI 0.34–0.52 at different drug ratios (Fig. 1e
and Supplementary Fig. 1B–D). Similarly, MV411 and MOLM13-
showed CI 0.21 and 0.29, respectively (Fig. 1f, g). There was no
benefit in using the combination treatment on the TP53 mutated
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cell lines (Fig. 1h–j) (CI for all mutant TP53 lines > 1). To
confirm these results we also calculated drug synergy by the Bliss
method27. This also showed substantially greater and more
consistent synergy (Bliss score >0) of the combination in TP53
wild-type cells, across a range of drug doses (Supplementary
Fig. 1E–J). The results of the cell viability studies in the TP53
wild-type OCI-AML3 cell line were corroborated by annexin
V/propidium iodide flow cytometry assay. We observed marked
enhancement of apoptosis specifically (annexin V positive) and/
or cell death by apoptosis or other mechanisms (annexin V/PI
positive), compared to either single drug alone (Supplementary
Fig. 1K–M). Enhanced killing of the combination-treated cells
was accompanied by a clear increase in cleaved PARP (Fig. 1k), a
marker of pro-apoptotic caspase activation, showing that the drug
A C 
H 
0
20
40
60
80
100
N
o
rm
a
liz
e
d
 
lu
m
in
e
s
c
e
n
c
e
 (
%
 R
L
U
) 
 *** 
*** 
N 
O L 
coefficient of drug interaction (CDI) 
P
 v
a
lu
e
 o
f 
n
u
m
e
ra
to
r 
v
s
 
d
e
n
o
m
in
a
to
r 
o
f 
C
D
I  
0.5 1 20.4
0.01
0.05
0.1
1
Synergistic Antagonistic 
P=0.05 
B 
F 
M 
0
3000
6000
9000
12000
MOLM13 
Nutlin-3 
CPI203 
Combo 
G 
CI=0.29 
V
ia
b
ili
ty
 (
R
F
U
) 
Nutlin-3 ( M) 
CPI203 (nM) 
0
 
2
.5
 
5
 
1
0
 
0
 
2
0
0
 
4
0
0
 
8
0
0
 
0
500
1000
1500
2000
V
ia
b
ili
ty
 (
R
F
U
) CI>1 
KG1a 
Nutlin-3 ( M) 
CPI203 (nM) 
0
 
2
.5
 
5
 
1
0
 
0
 
2
0
0
 
4
0
0
 
8
0
0
 
Nutlin-3 
CPI203 
Combo 
0
3500
7000
10500
14000 MV411 
CI=0.21 
V
ia
b
ili
ty
 (
R
F
U
) 
Nutlin-3 ( M) 
CPI203 (nM) 
0
 
2
.5
 
5
 
1
0
 
0
 
2
0
0
 
4
0
0
 
8
0
0
 
Nutlin-3 
CPI203 
Combo 
OCI-AML3 
p53 
MDM2 
CDKN1A 
β
µ
-Actin 
0 2.5 5 10 20 
Nutlin-3 ( M) 
42kDa 
21kDa 
90kDa 
53kDa 
THP1 KG1a 
CPI203 (nM) 
β-Actin 
C-MYC 
0 
CPI203 (nM) CPI203 (nM) 
OCI-AML3 
0 0 
42kDa 
67kDa 
I J 
0
300
600
900
1200
Nutlin-3 
CPI203 
Combo 
V
ia
b
ili
ty
 (
R
F
U
) 
0
 
2
.5
 
5
 
1
0
 
0
 
2
0
0
 
4
0
0
 
8
0
0
 
KASUMI-1 
CI>1 
Nutlin-3 ( M) 
CPI203 (nM) 
Nutlin-3 
CPI203 
Combo 
β-actin 
PARP 
K 
Full length 
Cleaved 
42kDa 
116kDa 
89kDa 
β-actin 
p53 
42kDa 
53kDa 
BRD4L 
+Dox  
BRD4S 
β-actin  42kDa 
250kDa 
100kDa 
V
ia
b
ili
ty
 (
R
F
U
) 
0
 
2
.5
 
5
 
1
0
 
0
 
2
0
0
 
4
0
0
 
8
0
0
 
Nutlin-3 
CPI203 
Combo 
Nutlin-3 ( M) 
CPI203 (nM) 
0
1000
2000
3000
4000
THP1 
CI>1 
0.0
500.0
1000.0
1500.0
2000.0
V
ia
b
ili
ty
 (
R
F
U
) 
Nutlin-3 ( M) 
CPI203 (nM) 
0
 
2
.5
 
5
 
1
0
 
0
 
2
0
0
 
4
0
0
 
8
0
0
 
CI=0.34 
OCI-AML3 E D 
OCI-AML3 
Most synergistic area score: 34.0 
Average Bliss synergy score: 13.9 
P 
0 
ns 
*** 
µ
µµµ
µ µ
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20378-8 ARTICLE
NATURE COMMUNICATIONS |          (2021) 12:241 | https://doi.org/10.1038/s41467-020-20378-8 | www.nature.com/naturecommunications 3
combination induces apoptosis in these TP53 wild-type
AML cells.
Confirming a requirement for wild-type TP53 for the drug
combination to induce super-additive cell death, we knocked
down p53 using shRNA in the TP53 wild-type OCI-AML3 cell
line which abrogated the benefit of the drug combination (Fig. 1l,
m). To similarly confirm that the effects of CPI203 were mediated
via inhibition of a BET family member, we asked whether the
enhanced killing by the MDM2i/BETi combination was recapi-
tulated by MDM2i together with BRD4 knockdown. Indeed,
inducible shRNA-mediated knockdown of BRD4 markedly
potentiated killing by MDM2i (Fig. 1n, o). In addition, we used
BET PROTACs to selectively and completely induce degradation
of BRD4 in cells (Supplementary Fig. 1N)28,29. Consistent with
BETi, BET degraders (BETd-260 and ARV-825) synergize with
MDM2i to suppress cell viability in 3 wild-type TP53 cell lines
(OCI-AML3, MOLM13, MV411) (Fig. 1p and Supplementary
Fig. 1O–S). Taken together, in primary human AML blasts and
human AML cell lines, we conclude that, in AML expressing
wild-type p53, BETi inhibit BRD4 to enhance cell killing
by MDM2i.
BETi and MDM2i cooperate to eradicate AML in mouse
models. Next, we asked whether the drug combination shows
superior anti-leukemic activity to the single agents, in two murine
models of AML. Trib2 is an oncogene capable of causing AML in
mice through down-regulation of the transcription factor C/
EBPα, a gene that is mutated in 15% of cases of AML in
humans30. Following confirmation by PCR and Sanger sequen-
cing that blasts from mice with AML driven by Trib2 expressed
wild-type p53 (data not shown), we first confirmed superior
eradication of the murine leukemic cells by the drug combination
compared to the two single drugs in vitro (Fig. 2a–c), recapitu-
lating the effect in human cells. For the purposes of subsequent
in vivo work we wanted to use clinical-grade drugs. We used the
clinical-grade BETi CPI0610 (Constellation Pharmaceuticals) and
MDM2i RG7112 (Roche Pharmaceuticals). RG7112 has been
tested as a single agent in relapsed refractory AML7, showing
modest activity, and is better suited to studies with murine AML
than human-optimized RG73889. CPI0610 is currently being
tested in early-stage human clinical trials and has been reported
to be well-tolerated31. For our experiments, we also identified
well-tolerated drug doses in mice, based on a 21-day drug pilot
experiment, assessing weight loss and myeloid cell counts (in
bone marrow), B cells (in spleen), and T cells (in thymus) in non-
leukemic normal healthy mice (Supplementary Fig. 2A, B). A
total of 40 C57BL/6 mice (10 mice each for vehicle, both single
drugs and the combination) were sub-lethally irradiated and
0.85 × 106 Trib2 AML blasts injected via their tail veins. Myelo-
blasts expressed GFP from the same retroviral construct as Trib2
for disease tracking. 21 days of drug treatment was commenced in
all leukemic mice, post confirmation of comparable disease
engraftment between groups (data not shown). Three mice from
each treatment group were sacrificed after the first 48 h of drug
treatment, GFP+ blasts recovered from bone marrow, RNA
extracted and qPCR performed to demonstrate that RG7112
increased expression of CDKN1A and CPI0610 reduced levels of
c-MYC (Fig. 2d, e), as expected if the drugs engage their
respective targets. After 21 days of treatment, all remaining mice
were sacrificed (n= 7 for each group, except n= 6 for vehicle
because 1 succumbed to disease 15 days post engraftment) and
abundance of GFP+ AML blasts in bone marrow determined by
FACS. The drug combination demonstrated significantly
enhanced anti-leukemic activity compared to either single drug
alone, measured in bone marrow (Fig. 2f, g), spleen, and thymus
(Supplementary Fig. 2C). In bone marrow and spleen the CDI
was <1 (0.017 and 0.38 respectively), indicating synergy in vivo.
Following demonstration that the drug combination was
tolerable and efficacious at the end of the treatment period, we
assessed if the drug combination could confer a survival
advantage over the single agents in mice with Trib2-driven
AML. Sub-lethally irradiated cohorts of mice were again injected
with GFP+ Trib2 AML blasts and, following comparable disease
engraftment between groups (Supplementary Fig. 2D), were
Fig. 1 MDM2 and BET inhibitors combine to enhance killing of primary human AML blasts and AML cell lines with wild-type TP53. a Primary human
patient AML blasts (n= 15) were treated with indicated drugs (2.5 μM nutlin-3 alone, 200 nM CPI203 alone, and the two in combination) and cell viability
was assessed by CellTiter-Glo assay after 48 h (***=p≤ 0.001, two-tailed unpaired t-test). b Scatter plot of coefficient of drug interaction (CDI) and
synergy significance in primary human patient blasts from A. CDI was calculated as follows: CDI=AB/(AxB). AB is the fraction of cells surviving (0–1.0) in
the combination of drugs (nutlin-3+ CPI203); A (nutlin-3) and B (CPI203) are the fraction of cells surviving in each of the single drugs. CDI value (x-axis)
<1 (left), =1, or >1 (right) indicates that the drugs are synergistic, additive or antagonistic, respectively. p value (y-axis) ≤0.05 indicates significance (top).
The p value was generated comparing AB and AxB (***=p≤ 0.001, two-tailed unpaired t-test). Red diamonds, TP53 wild-type. Open diamonds, TP53 status
unknown. c Western blots performed on the OCI-AML3 cell lines assessing expression of p53, MDM2, and CDKN1A after 24 h of drug treatment with
increasing doses of nutlin-3. d Western blots performed on the OCI-AML3, THP1, and KG1a cell lines, assessing the expression of C-MYC after 24 h in
indicated doses of CPI203. e OCI-AML3 cell viability (each treatment in triplicate) was assessed by resazurin assay after 72 h, using a treatment ratio of
CPI203:nutlin-3 of 1:12.5. Mean ± Standard deviation of 3 independent replicates is shown. fMV411 cell viability (each treatment in triplicate) was assessed
by resazurin assay after 72 h, using a treatment ratio of CPI203:nutlin-3 of 1:12.5. Mean ± Standard deviation of 3 independent replicates is shown.
gMOLM13 cell viability (each treatment in triplicate) was assessed by resazurin assay after 72 h, using a treatment ratio of CPI203:nutlin-3 of 1:12.5. Mean
± Standard deviation of 3 independent replicates is shown. h KG1a cell viability (each treatment in triplicate) was assessed by resazurin assay after 72 h,
using a treatment ratio of CPI203:nutlin-3 of 1:12.5. Mean ± Standard deviation of 3 independent replicates is shown. i THP1 cell viability (each treatment in
triplicate) was assessed by resazurin assay after 72 h, using a treatment ratio of CPI203:nutlin-3 of 1:12.5. Mean ± Standard deviation of 3 independent
replicates is shown. j KASUMI-1 cell viability (each treatment in triplicate) was assessed by resazurin assay after 72 h, using a treatment ratio of CPI203:
nutlin-3 of 1:12.5. Mean+ /- Standard deviation of 3 independent replicates is shown. k Cleavage of PARP as assessed by Western blot analysis according
to treatment condition after 24 h treatment of the OCI-AML3 cell line. l Western blot assessing expression of p53 in the OCI-AML3 cell line, harboring
empty vector, scrambled shRNA p53 or shRNA p53. m Cell viability as assessed by trypan blue in OCI-AML3 cells harboring empty vector or shRNA p53,
treated for 72 h with vehicle, 200 nM CPI203, 2.5 μM nutlin-3 or the drug combination (***=p≤ 0.001, two-tailed unpaired t-test, n= 3, Means ± SD are
shown). n Western blot analysis of shRNA-mediated knockdown of BRD4 (shRNA induced by 0.5ug/ml doxycycline for 72 h). o FACS analysis of
apoptosis (annexin V and PI) in OCI-AML3 cells expressing empty-vector or shRNA BRD4 (doxycycline-inducible), treated with vehicle, doxycycline,
nutlin-3, and the combination of nutlin-3 and doxycycline for 72 h (***=p≤ 0.001, **=p≤ 0.01, two-tailed unpaired t-test, n= 3, Means ± SD are shown).
p Excess Over Bliss plot showing synergistic effects between RG7388 and BETd-260 in OCI-AML3 cells. Cell viability (each treatment in quadruplicate)
was assessed by CellTiter-Glo after 24 h. Bliss synergy scores were indicated.
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treated with vehicle, single drugs, or combination for 21 days.
FACS analysis of peripheral blood at the end of drug treatment
confirmed the synergy of the drug combination in eradication of
GFP+ blasts (CDI= 0.031, Supplementary Fig. 2E). After
completion of the 21-day drug cycle, mice were closely monitored
for signs of leukemia and culled at an ethical endpoint. Although
the combination-treated mice did ultimately succumb to disease
after cessation of treatment, indicative of low-level residual
disease, the combination-treated mice did have a statistically
significant survival advantage compared with the single agent-
treated mice (Fig. 2h). This underscores the anti-leukemic activity
of the combination in this model.
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To confirm that these findings were not confined to this
leukemia, given the heterogeneous nature of AML, we sought to
demonstrate that the drug combination could also elicit improved
killing in a distinct AML mouse model, namely the MLL-AF9
mouse model. This aggressive AML, driven by a KMT2A
translocation occurring in ~5% of human adult AML, is well-
established and frequently utilized for testing novel drugs for
AML32. We first confirmed by DNA sequencing that murine
MLL-AF9 cells harbored wild-type p53 (data not shown), and
that at most drug ratios the drug combination enhanced killing of
MLL-AF9 myeloblasts in vitro (Fig. 2i). Sub-lethally irradiated
cohorts of mice were injected with GFP+ MLL-AF9 AML blasts
and cohorts of comparable disease burden (Supplementary
Fig. 2F) were treated with vehicle, single drugs or combination
for 21 days. Analysis of disease burden in peripheral blood after
7 days of treatment, based on GFP+ blasts and CD11blow Gr1-
expressing immature blasts known to expand in AML32,
demonstrated the superiority of the drug combination over single
agents in disease suppression (CDI= 0.36, Fig. 2j and Supple-
mentary Fig. 2G). Moreover, although at this high dose of
leukemic cells (200,000 per mouse) the vehicle-treated mice
succumbed to disease in less than 2 weeks, the drug combination-
treated mice showed a robust and highly statistically significant
survival advantage compared with the single agent-treated mice
in the MLL-AF9 model (Fig. 2k). As expected, the 4 treatment
cohorts showed comparable disease burden at the time of cull
based on similar disease symptoms (Supplementary Fig. 2H). We
conclude that in two different p53 wild-type mouse models of
AML, the drug combination is superior to the single agents in
suppressing disease and extending survival.
BETi potentiate activation of p53 by MDM2i. We set out to
define the basis of the enhanced combined toxicity of BETi and
MDM2i towards AML cells. In the OCI-AML3 cell line, treat-
ment with single-agent CPI203 reduced the protein abundance of
c-MYC as expected, but this was not substantially further reduced
by the drug combination (Fig. 3a). Likewise, nutlin-3 modestly
increased abundance of p53, but again this was not enhanced by
the drug combination (Fig. 3a). Therefore, synergy does not
appear to result from a concerted effect of the drugs on stabili-
zation of p53 nor repression of c-MYC. Previously, a combination
of MDM2i and the BCL2 inhibitor Navitoclax has been shown to
synergize in killing AML cells10. Since BETi downregulate
expression of BCL2 and upregulate expression of BCL2 inhibitor
BIM14,33, we wondered whether BETi-mediated downregulation
of BCL2 activity contributes to synergy between BETi and
MDM2i. We confirmed that BETi CPI203 downregulates BCL2
(Fig. 3b). However, ectopic expression of BCL2 did not suppress
killing by the combination (Fig. 3c, d). These results do not
eliminate a role for regulation of BCL2 family proteins (including
BIM) in drug combination-induced AML cell killing, but do
indicate that BETi-mediated repression of BCL2 is not necessary
for killing by the combination.
To obtain unbiased insight into the potential basis of enhanced
combined toxicity, we set out to compare the gene expression
profiles of OCI-AML3 cells treated with either vehicle, CPI203 (200
nM), nutlin-3 (2.5 μM), or the drug combination. OCI-AML3 cells
were treated with vehicle, CPI203 200 nM, nutlin-3 2.5 μM, and the
drug combination for 24 h, then RNA was extracted and analyzed
by RNA-seq. Principal Component Analysis confirmed the
expected difference between the drug treatments at the gene
expression level (Supplementary Fig. 3A). Following treatment with
CPI203, either as a single agent or as part of the drug combination,
~6,100 coding genes significantly changed expression relative to
vehicle (Supplementary Fig. 3B–D). A much smaller number of
genes (174) significantly changed expression following treatment
with nutlin-3 only (Supplementary Fig. 3B–D). This was anticipated
given the broad effects of BET inhibition, at least in part a
consequence of down-regulation of c-MYC, compared with a more
restricted number of known p53 target genes14–16. We reasoned
that synergistic killing by the drug combination might be under-
pinned by synergistic changes in gene expression. Indeed, visual
analysis of a heatmap of significantly changed genes revealed
clusters of apparently synergistically up and down-regulated genes
(Supplementary Fig. 3E). Quantitative analysis yielded 252 genes
that were synergistically up-regulated and 94 genes that were
synergistically down-regulated by the drug combination (Fig. 3e
and Supplementary Data 1 and 2). Ingenuity Pathway Analysis
(IPA) analysis showed that the synergistically down-regulated genes
were enriched in cell cycle genes (Supplementary Fig. 3F). The
synergistically up-regulated genes were most significantly enriched
in genes involved in the p53 pathway (Supplementary Fig. 3 F). Of
116 known high-confidence p53 target genes34, 24 were synergis-
tically upregulated by the drug combination (Fig. 3f and
Supplementary Fig. 3G). Synergistically up-regulated TP53 target
genes included ANKRA2, ARHGEF3, BBC3 (PUMA), BTG2,
CDKN1A, DRAM1, FUCA1, GADD45A, GDF15, IER5, LAPTM5,
MDM2, PMAIP1, RAP2B, RRM2B, SERTAD1, SESN2, TGFA,
TNFRSF10B, TNFRSF10D, TP53I3, TP53INP1, ZMAT3 and
ZNF337 (Fig. 3f). Representative sequence tracks of p53 target
genes GDF15, CDKN1A and BBC3 are shown (Supplementary
Fig. 2 MDM2 and BET inhibitors cooperate to eradicate AML in in vivo mouse models. a Primary murine Trib2 AML blasts, treated in vitro for 72 h with
vehicle, 200 nM CPI203, 2.5 μM nutlin-3, or the drug combination. Cell death assessed by flow cytometry using Annexin-V and PI staining (***=p≤ 0.001,
two-tailed unpaired t-test, n= 3, Means ± SD are shown). b A representative example of the data summarized in Fig. 2a (Gating strategy for sorting GFP
positive cells was live cells>cell profile>single cells>GFP positive cells). c A time course of viable cell counts as assessed by trypan blue staining, of primary
murine Trib2 AML blasts, according to treatment condition (Error bars are SEM, n= 3, Means ± SD are shown). d qPCR assessment of CDKN1A
expression in GFP+ blasts recovered from bone marrow from three mice sacrificed after 48 h treatment with RG7112 relative to vehicle (**=p≤ 0.01, two-
tailed unpaired t-test, n= 3, Means ± SD are shown). e qPCR assessment of C-MYC expression in GFP+ blasts recovered from bone marrow from
three mice sacrificed after 48 h treatment with CPI0610 relative to vehicle (***=p≤ 0.001, two-tailed unpaired t-test, n= 3, Means ± SD are shown).
f Assessment of the disease burden in the bone marrow according to treatment condition, at the end of 21 days of treatment in vivo; disease burden
assessed by flow cytometry to measure percent GFP+ blasts (****=p≤ 0.0001, two-tailed unpaired t-test, from left to right: n= 6, 7, 7, 7, Means ± SD are
shown). g A representative example of the data summarized in Fig. 2f (Gating strategy for sorting GFP Positive cells was live cells>cell profile>single
cells>GFP positive cells.). h A survival analysis of mice transplanted with Trib2-driven AML according to treatment condition (****=p≤ 0.0001, from
Kaplan–Meier estimator). i Primary murine MLL-AF9 AML blasts treated in vitro with vehicle, 200 nM CPI203, 2.5 μM nutlin-3, and the drug combination
for 72 h. Cell viability assessed by resazurin (Means ± SD are shown, n= 3). j Analysis of disease burden in peripheral blood, based on percent CD11blow
Gr1+ blasts, after 7 days of treatment, according to drug condition (***=p≤ 0.001,****=p≤ 0.0001, two-tailed t-test, from left to right, n= 4, 9, 9, 10,
Means ± SD are shown). k A survival analysis of mice transplanted with MLL-AF9-driven AML, according to treatment condition (****=p≤ 0.0001, from
Kaplan–Meier estimator).
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Fig. 3H). Synergistic upregulation of p53 targets, CDKN1A and
BBC3, by the drug combination was confirmed at the RNA level by
qPCR and the protein level by western blot (Fig. 3g–i), and at the
RNA level for GDF15, TP53INP1 and FUCA1 (Fig. 3j–l). We
conclude that enhanced toxicity of the drug combination is
associated with enhanced expression of p53 target genes.
To confirm that expression of these p53 target genes is indeed
dependent on p53, we generated cells expressing shRNA to knock
down p53 (or empty vector control cells) and treated with single
or combination drugs (Fig. 3m). p53-deficient cells failed to
upregulate CDKN1A in response to nutlin-3 or combination
(Fig. 3m and Supplementary Fig. 3I). Principal Component
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Analysis (PCA) of RNA-seq data confirmed that p53 knock down
blunted the effect of the drug combination on the whole
transcriptome (data not shown). Similar to the previous
experiment, 214 genes were calculated to be synergistically
upregulated by the drug combination in control cells. Of these,
204 were dependent on p53 for their synergistic upregulation
(Supplementary Data 3). Of the 116 bona fide p53 target genes34,
19 were upregulated in control AML3 cells expressing p53 (12 of
which were in common with the previous experiment (Fig. 3f, n
and Supplementary Fig. 3J). None of these 19 p53 target genes
was synergistically upregulated in drug combination-treated p53-
deficient cells (Fig. 3n). To dissect which p53 target genes are
required for enhanced combined drug toxicity in OCI-AML3
cells, we used CRISPR/Cas9 to generate derivatives of OCI-AML3
cells lacking CDKN1A, BBC3 and NOXA. Consistent with the
observation that drug combination synergy is linked to cell death
(Fig. 1), inactivation of CDKN1A, a well-known effector of p53-
mediated cell cycle arrest but not apoptosis, did not affect synergy
of the combination (Supplementary Fig. 3K). More surprisingly,
inactivation of pro-apoptotic p53-target genes BBC3 and NOXA
on their own did not significantly affect cell killing (data not
shown). However, combined inactivation of BBC3 and NOXA
markedly blunted drug combination-induced cell killing (Fig. 3o,
p). Together, these results unexpectedly show that BET inhibition
potentiates activation of p53. WT p53 is required for enhanced
expression of p53 target genes by BET inhibition and at least two
of these genes, BBC3 and NOXA, are required for enhanced
combined toxicity towards AML by dual BET and MDM2
inhibition.
BET inhibition relieves BRD4-mediated repression of p53
target genes. We set out to define the molecular mechanism by
which BET inhibition potentiates activation of p53. Induction of
BBC3 by nutlin-3 was also potentiated by BRD4 knock down,
confirming that BETi acts, at least in part, by inhibition of BRD4
(Fig. 4a, b). We initially considered three non-mutually exclusive
testable possibilities for how BETi/inhibition of BRD4 potentiates
activation of p53 by MDM2i. First, we postulated that the BETi
might stabilize p53 target mRNAs. Second, we considered the
possibility that BETi might, directly or indirectly, promote
expression of known p53 activators that synergize with
p53 stabilized by MDM2i to potentiate activation of the p53
pathway. Third, we hypothesized that BETi might promote p53
binding to its cognate target genes. To test whether BETi stabi-
lized expression of p53 target mRNAs, OCI-AML3 cells were
treated with vehicle, single drugs or combination and then 2 h
later with actinomycin D to inhibit new transcription. Abundance
of p53 target mRNAs was determined by qPCR over a time-
course, allowing relative assessment of mRNA half-life. Figure 4c,
d demonstrates that, compared to either single agent, the drug
combination did not promote stability of CDKN1A or BBC3
mRNAs.
To test the role of selected p53 activators, we mined our RNA-
seq data for known p53 activators upregulated by BETi. Based on
analysis of RNA-seq data, at least two known p53 activators, JNK
and 53BP135,36, were upregulated by BETi alone and the drug
combination (Fig. 4e). qPCR confirmed significant upregulation
of JNK by BETi and an upward trend for 53BP1 (Fig. 4f, g). To
test a role for JNK or 53BP1 in activation of p53, we knocked
them down by lentivirus-delivered shRNA (Fig. 4h, i). However,
neither was required for enhanced toxicity of the MDM2i and
BETi combination (Fig. 4j, k).
To test whether the drug combination promoted binding of
p53 to its target genes compared to either single agent alone, we
performed ChIP-seq to assess p53 binding across the whole
genome in OCI-AML3 cells. Three independent replicates of
OCI-AML3 cells were treated with vehicle control, CPI203 200
nM, nutlin-3 2.5 μM or the drug combination. Cells were
harvested for ChIP 6 h after drug treatment, since qPCR and
western blot analysis showed that upregulation of p53 target
genes was already detectable at this time (data not shown).
Analysis of ChIP-seq data showed that the mean p53 peak width
under all treatment conditions was ~400 bp (Supplementary
Fig. 4A). The overall genome distribution of sites under all
conditions was similar and very few sites were unique to drug
combination-treated cells (Supplementary Fig. 4B, C). In fact, the
drug combination tended to decrease the total number of p53
binding sites, compared to nutlin-3 alone (Fig. 4l, Supplementary
Fig. 4C, D). Most of the 252 synergy up genes did not bind p53 in
either nutlin-3 or combination-treated cells (Supplementary
Fig. 4E), suggesting that they are not direct p53 targets and their
activation by nutlin-3 is indirect. For the 24 synergy up genes that
are also bona fide p53 target genes, most bound p53 in the nutlin-
3-treated cells, as expected, but this was not increased in
Fig. 3 BET inhibitors potentiate activation of p53 target genes by p53. a Western blot of C-MYC and p53 in OCI-AML3 cells treated for 24 h with
vehicle, 200 nM CPI203, 2.5 μM nutlin-3, and the drug combination. b Western blot for BCL-2 in OCI-AML3 cells treated for 24 h with vehicle, 200 nM
CPI203, 2.5 μM nutlin-3, and the drug combination. c Western blot for BCL-2 comparing the control OCI-AML3 and cells over-expressing BCL-2. d Cell
killing as assessed by flow cytometry using Annexin-V and PI staining of OCI-AML3 control (empty vector) cells versus OCI-AML3 over-expressing BCL-2,
according to treatment condition (p-value >0.05 by two-tailed unpaired t-test, Means ± SD are shown, n= 3). e A heat map of genes synergistically
regulated by the drug combination determined by RNA-seq of OCI-AML3 cells according to treatment condition (24 h). Genes synergistically up-regulated
(Up) by the drug combination were rigorously identified as those where C/(A+ B)= > 1.25 and combination FPKM>DMSO FPKM, and synergistically
down-regulated genes (Down) where C/(A+ B)= > 1.25 and combination FPKM<DMSO FPKM (where C= combination FPKM – DMSO FPKM; A=
nutlin-3 FPKM – DMSO FPKM; B= CPI203 FPKM – DMSO FPKM). f A heat map of 24 high confidence p53 target genes that are synergistically up-
regulated or down-regulated in OCI-AML3 according to treatment condition. g qPCR analysis of CDKN1A expression in OCI-AML3 under indicated
treatments for 24 h (**=p≤ 0.01, two-tailed unpaired t-test, Means ± SD are shown, n= 3). h qPCR analysis of BBC3 expression in OCI-AML3 under
indicated treatments for 24 h (****=p≤ 0.0001, two-tailed unpaired t-test, Means ± SD are shown, n= 3). i Western blot analysis of p53 targets BBC3 and
CDKN1A in OCI-AML3 according to treatment condition. j qPCR expression analysis of TP53INP1 in OCI-AML3 under indicated treatments for 24 h (*=p≤
0.05, two-tailed unpaired t-test, Means ± SD are shown, n= 3). k qPCR expression analysis of GDF15 in OCI-AML3 under indicated treatments for 24 h
(**=p≤ 0.01, two-tailed unpaired t-test, Means ± SD are shown, n= 3). l qPCR expression analysis of FUCA1 in OCI-AML3 under indicated treatments for
24h (*=p≤ 0.05, two-tailed unpaired t-test, Means ± SD are shown, n= 3). m Western blot analysis of p53 and CDKN1A in OCI-AML3 cells and OCI-
AML3 cells harboring shRNA p53 according to treatment condition. n A heat map of an RNA-seq data of 19 high confidence p53 target genes that are
synergistically up-regulated by the drug combination in control (empty-vector) OCI-AML3 cells, versus shRNA p53 OCI-AML3 cells, according to
treatment condition. o Western blot analysis of BBC3 and NOXA in control (empty vector) OCI-AML3 cells, and OCI-AML3 cells harboring CAS9 and
sgRNAs against PUMA and NOXA. p FACS analysis of cell death (annexin VI and PI) in control OCI-AML3 cells or cells in which PUMA and NOXA were
knocked out by CRISPR/CAS9, under indicated conditions for 72 h (*=<additive. **=>additive, two-tailed unpaired t-test, Means ± SD are shown, n= 3).
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combination-treated cells (Fig. 4m). Instead, at p53 target genes,
p53 binding tended to decrease in combination-treated cells
compared to nutlin-3-treated cells (Fig. 4m), in line with the
global analysis (Fig. 4l and Supplementary Fig. 4C, D).
Examination of the sequence tracks for individual genes, such
as MDM2 and RRM2B, confirmed the observation that BETi, in
combination with nutlin-3, did not increase the binding of p53 to
its target genes (Fig. 4n, o). We ultimately conclude that
BET inhibition does not activate p53 by stabilizing its target
gene mRNAs, nor via promotion of activity of selected tested
known p53 activators, nor by increasing p53’s binding to its
target genes.
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At this point, closer inspection of the RNA-seq data revealed
that p53 was ranked as one of the top upstream regulators of
genes differentially expressed by CPI203 (Supplementary Fig. 5A).
Focused analysis of p53 target genes directly showed that CPI203
alone was sufficient to increase expression of many p53 target
genes in OCI-AML3 cells (Supplementary Fig. 5B, C). For several
p53 target genes this was confirmed by qPCR after treatment with
CPI203 or knock down of BRD4 by lentivirus-encoded shRNA
(Supplementary Fig. 5d, e). Inhibition of BET family proteins
with a potent PROTAC BET degrader BETd-260 strongly
upregulated expression of p53 target gene p21 at the protein
level (Supplementary Figs. 1N and 5F)28. Since previous results
established a critical role for BRD4 (Figs. 1n, o and 4a, b), these
data raised the possibility that BRD4 might be a repressor of p53
target gene expression. To test this, we better characterized the
effect of BETi and nutlin-3 on BRD4’s chromatin binding. We
performed ChIP-seq analysis to determine genomic localization
of BRD4 in control, single drug and combination-treated cells. In
control OCI-AML3 cells, BRD4 reproducibly bound ~9800 sites
occupying ~27Mb across the genome (Fig. 5a, b and Supple-
mentary Fig. 6A). In nutlin-3-treated cells, a similar number of
BRD4 binding sites and total genome occupancy was observed
(Fig. 5a, b and Supplementary Fig. 6B), and the majority of
binding sites overlapped between control and nutlin-3-treated
cells (Supplementary Fig. 6C). As expected, in BETi and
combination-treated cells, the number of reproducible BRD4
binding sites was greatly decreased (Fig. 5a, b and Supplementary
Fig. 6C–E). In both control and nutlin-3-treated cells the majority
of the BRD4 binding sites were at annotated gene promoters
(Fig. 5C). Across all genes, in vehicle-treated cells BRD4 binding
correlated with gene expression (Supplementary Fig. 6F) and
globally a loss of BRD4 on treatment with BETi was associated
with a small but significant decrease in gene expression
(Supplementary Fig. 6G), consistent with the role of BRD4 as a
global transcriptional activator12.
To evaluate the role of BRD4 in potentiation of p53 target gene
expression by BETi, we considered BRD4 binding in nutlin-3 vs
combination-treated cells. For the 24 synergy up genes that are
also bona fide p53 target genes (Fig. 3f), 22 bound BRD4 in
nutlin-3-treated cells but only 2 bound BRD4 in combination-
treated cells (Fig. 5d). This interpretation was supported by
analysis of individual gene loci, e.g. CDKN1A and BBC3 (Fig. 5e,
f). As noted above, the vast majority of the synergy up p53 target
genes also bind p53 in both nutlin-3 and combination-treated
cells (Figs. 4n, n and 5d). In other words, synergy up p53 target
genes, tend to bind p53 and BRD4 in nutlin-3-treated cells but
p53 only in combination-treated cells (Fig. 5d–f). These results
suggest that in AML cells, BRD4 may act as a repressor of p53
target genes. In line with this idea, treatment of OCI-AML3 cells
with CPI203 modestly activated a number of p53 target genes,
even in the absence of nutlin-3, e.g., PMAIP1, RAP2B, FUCA1,
and others (Fig. 3f). To directly test the ability of BRD4 to repress
p53 target genes, we ectopically expressed the short form of BRD4
(BRD4S) in AML3 cells treated with nutlin-3 to stabilize p53.
Cells ectopically expressing BRD4S activated p53 target genes
CDKN1A and PUMA to a lesser extent than empty vector cells
upon treatment with nutlin-3 (Fig. 5g–i). Measured against a
number of other p53 target genes, there was an invariable trend
towards repression by BRD4S (Supplementary Fig. 7A–H). The
repressive effect of BRD4S was confirmed using a stably
integrated p53 fluorescent/luminescent reporter gene (Supple-
mentary Fig. 6I, J). BRD4S also repressed p53 target gene
expression in wild-type TP53 MOLM13 cells (Supplementary
Fig. 7K–N). These results suggest that in AML, BRD4 is able to
bind p53 target genes and can repress their activation, even when
p53 is bound. Displacement of BRD4 by BET inhibition relieves
this repression, leaving p53 free to activate its pro-apoptotic
targets, thereby accounting for the enhanced killing of AML by
combined MDM2 and BET inhibition.
Discussion
In this study, we show that BRD4 inhibition together with p53
activation results in enhanced anti-leukemia activity both in vitro
and in vivo, in AML retaining wild-type TP53, compared to either
inhibition alone. Apparent synergy depends on wild-type TP53, is
linked to enhanced activation of p53 by BETi and depends on the
expression of at least some p53 target genes, namely BBC3 and
NOXA. Regarding the mechanism underlying this enhanced anti-
leukemia activity, we eliminated some obvious candidates, such as
the binding of p53 to its target genes and the stabilization of p53
target mRNAs. Instead, we present evidence that the basis of this
enhanced anti-leukemia activity is via relief of an unexpected
repressive effect of BRD4 on expression of p53 target genes,
thereby unleashing the full pro-apoptotic activity of p53 stabilized
by MDM2i.
Through its role as a “reader” of acetylated lysine residues,
BRD4 is widely regarded as a driver of transcriptional activation.
Mechanistically, BRD4 promotes gene expression via the
recruitment and activation of P-TEFb, which drives RNA poly-
merase II-dependent transcription37. However, some reports have
implicated BRD4 in transcriptional repression. Although some
reports have implicated BRD4S preferentially as the repressive
isoform, for example of transcriptionally silent latent HIV virus
by recruitment of repressive SWI/SNF chromatin remodeling
Fig. 4 BET inhibitors do not stabilize p53 target mRNAs nor increase binding of p53 to target genes. a qPCR assessment of expression of CDKN1A in
control (empty-vector) OCI-AML3 cells versus OCI-AML3 cells harboring shRNA against BRD4, comparing treatment with vehicle and 2.5 μM nutlin-3 (p-
value >0.05 by two-tailed unpaired t-test, Means ± SD are shown, n= 3). b qPCR assessment of expression of BBC3 in control (empty-vector) OCI-AML3
cells versus OCI-AML3 cells harboring shRNA against BRD4, comparing treatment with vehicle and 2.5 μM nutlin-3 (two-tailed unpaired t-test, Means ±
SD are shown, n= 3, ** means p-value < 0.01). c qPCR analysis of expression of CDKN1A in OCI-AML3 cells treated with Actinomycin D over the indicated
time-course (0, 2, 4, 6, 8 h) and under the indicated drug treatments (Means ± SD are shown, n= 3). d qPCR analysis of BBC3 in OCI-AML3s treated with
Actinomycin D over the indicated time-course (0, 2, 4, 6, 8 h) and under the indicated drug treatments (Means ± SD are shown, n= 3). e Heat map
showing expression of JNK and 53BP1 in OCI-AML3 cells after the indicated drug treatments for 24 h. f qPCR expression analysis of 53BP1 in OCI-AML3
cells after indicated drug treatments for 24 h (two-tailed unpaired t-test, Means ± SD are shown, n= 3). g qPCR expression analysis of JNK in OCI-AML3
cells after indicated drug treatments for 24 h (*=p≤ 0.05, two tailed unpaired t-test, Means ± SD are shown, n= 3). hWestern blot of 53BP1 in OCI-AML3
expressing either empty vector or shRNA 53BP1. i Western blot of JNK in OCI-AML3 cells expressing either empty vector or shRNA JNK isoform 1+
isoform 2. j FACS analysis of cell death (annexin VI and PI) in OCI-AML3 cells expressing empty-vector or shRNA 53BP1 after indicated drug treatments for
72 h. k FACS analysis of apoptosis (annexin VI and PI) in OCI-AML3 cells expressing empty-vector or shRNA JNK isoform 1 + isoform 2 after indicated
drug treatments for 72 h. l Total number of p53 binding sites across the genome (ChIP-seq) after indicated drug treatments for 6 h, present in at least 2 out
of 3 replicates. m Heat map of p53 binding at indicated genes in OCI-AML3 cells after indicated drug treatments for 6 h. n Sequence tracks of p53 binding
at MDM2 gene after indicated drug treatments for 6 h. o Sequence tracks of p53 binding at RRM2B gene after indicated drug treatments for 6 h.
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complexes38, other studies have shown that BRD4L also acts as a
repressor, for example of the HPV-encoded E6 gene and autop-
hagy genes by recruitment of histone methyltransferase G9A39,40.
Conceivably, a BRD4/G9A interaction is also involved in the
repression of p53 target genes. Previous studies have demon-
strated a physical interaction between p53 and BRD426,41. Wu
et al showed that BRD4 promotes the expression of p53 target
gene, CDKN1A, at least in 293 cells41. These studies raise the
possibility that in some contexts a p53/BRD4 physical interaction
promotes expression of p53 target genes, but in AML cells BRD4’s
interaction with p53 is co-opted into a repressive interaction that
silences p53 target genes and facilitates leukemogenesis. Our
demonstration that BRD4 acts as a repressor and silences p53
activity extends the repressive activity of BRD4 into an important
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new context and has important implications for AML patho-
genesis and candidate therapeutic approaches.
Regarding pathogenesis, across all human cancers, the TP53
tumor suppressor gene is the most frequently mutated gene42. In
mice, inactivation of p53 cooperates with activated RAS in leu-
kemogenesis43–45. However, although AML is, overall, a hetero-
geneous disease, surprisingly more than 90% of de novo AML
retain wild-type TP532,3, suggesting that human AML subtypes
employ alternative mechanisms to inactivate the p53 pathway5.
At least some AML dysregulate known p53 regulators, MDM2,
MDM4, and ARF5. Our data suggest that in some AML dysre-
gulation of BRD4 might also antagonize the p53 pathway to
facilitate leukemogenesis. Consistent with this idea, BRD4 exhi-
bits elevated expression in ~7% of AML46, and, in the majority of
cases, this is accompanied by wild-type TP53 (cBioportal).
With respect to novel candidate therapies for AML, our studies
suggest promising efficacy of the MDM2i and BETi combination
in AML. Previous studies have suggested that the efficacy of an
MDM2i and BETi combination in chronic myeloid leukemia
(CML) comes from dual targeting of the p53 and c-MYC path-
ways, by MDM2i and BETi respectively47. As a secondary con-
sequence of BETi-mediated downregulation of c-MYC, BETi can
activate at least one p53 target gene, CDKN1A, through loss of c-
MYC-mediated gene repression48. Thus, although our studies
indicate that TP53 wild type AML are typically sensitive to the
MDM2i/BETi combination, the dominant mechanisms under-
lying synergistic toxicity are likely to vary, especially given the
genetic heterogeneity of AML2,3. At least in OCI-AML3 cells
(representative of a recurrent AML genotype found in 10-15% of
AML, NPM1, and DNMT3A mutant and TP53 wild type), we
have shown an unexpected ability of BETi to directly potentiate
activation of p53 by MDM2i, via relief of BRD4-mediated gene
repression. Also in two mouse models, we observed markedly
enhanced anti-AML activity of the drug combination, compared
to either single drug alone. Of note here, however, we used a
clinical-grade MDM2i, RG7112, that has been optimized against
human MDM2i. Therefore, it is possible that our mouse studies
diminish the on-target toxicity of MDM2i toward normal healthy
mouse tissues, thereby increasing the tolerability and apparent
therapeutic window of the drug in this experimental setting.
Further validation of this novel drug combination, in terms of
efficacy and tolerability, in both animal models and human cells
is warranted.
The molecular heterogeneity of AML has been a hurdle to the
development of novel therapies of benefit to a substantial pro-
portion of patients. For example, NPM1, the most commonly
mutated gene in AML, is mutated in only 28% of AML and many
genes are recurrently mutated, but in less than 10% of patients,
for example, ASXL1, IDH2, RUNX1, and SRSF22,3. In contrast, in
pre-clinical studies, a substantial proportion of AMLs are rela-
tively sensitive to BETi and ~90% of AML express wild-type
TP532,3,14–16,48 suggesting that the MDM2i and BETi drug
combination can potentially target a majority of AML.
In summary, we demonstrate that MDM2 and BET inhibition
are synthetically lethal in AML with wild-type p53. We propose
that BRD4 represses transcription of p53 target genes, such that
when BETi block repression in the context of p53 stabilization by
MDM2i the p53 pathway is potently activated leading to
enhanced anti-leukemia activity, compared to either drug alone.
As single agents these compounds have been shown to be effec-
tive and quite well-tolerated in clinical trials49. Given the super-
iority of the combination over single drugs in our in vitro and
in vivo studies, a clinical trial employing these two agents as a
combination in AML retaining wild-type TP53 is justified.
Methods
Primary AML cells. A total of 15 AML patient samples were studied. All primary
bone marrow aspirates were taken from routine diagnostic specimens after the
informed consent of the patients. The project received approval from the local
ethics committee (Brighton and Sussex University Hospitals NHS Trust Research
and Development Committee) as The Brighton Blood Disorder Study, references
09/025/CHE and 09/H1107/1) and was conducted in accordance with the
Declaration of Helsinki. Mononuclear cells from patients diagnosed with AML
were isolated by Histopaque 1077 density gradient purification. They were stored
in the Brighton and Sussex Medical School (BSMS) tissue bank and plated at a
density of 40,000 cells/per well in the black 96 wells plates. Cells were plated in
80 μl of RPMI containing 10% FCS, 100 mM glutamine, 10,000 I.U/mL Penicillin,
and Streptomycin. Relevant co-variate data on patients can be found in Supple-
mental Data 8.
AML Cell lines. THP1 was obtained from ATCC, KASUMI-1, MOLM-13, and
OCI-AML3 from DSMZ, KG1a, and MV411 were gifted from Professor Mhairi
Copland and Dr. Xu Huang, respectively (both Paul O’Gorman Leukemia Research
Centre, Glasgow). The authenticity of all cell lines was confirmed by genotyping.
Cell lines were grown according to the vendors’ instructions, were incubated at
37 °C in a humidified incubator with 5% CO2, and passaged every 3–4 days. For
p53 activity assays with luciferase and GFP reporters, AML3 cells were stably
infected with pGF-p53-mCMV-EF1α-Puro lentivirus (https://systembio.com/shop/
pgf-p53-mcmv-ef1α-puro-ht1080-stable-cell-line/).
Mice. Study was approved by University of Glasgow Animal Welfare & Ethical
Review Board (AWERB) and carried out under UK Home Office regulation. Trib2-
expressing AML blasts30 from serial transplants were thawed and maintained in
medium (DMEM with 15% FBS+ 100 units/ml penicillin-streptomycin and 2 mM
L-glutamine) and supplemented with 10 ng/ml IL-3 (Peprotech, 213-13), 10 ng/ml
IL-6 (Peprotech 216-1) and 100 ng/ml SCF (Peprotech 250-03). MLL-AF9 cells32
were maintained in medium (RPMI with 20% FBS+ 100 units/ml penicillin
streptomycin and 2mM L-glutamine) and supplemented with 10 ng/ml IL-3
(Peprotech, 213-13). For in vivo experiments, mice were sub-lethally irradiated at
5.5 Gy, and 4 h later injected with 850,000 cells for the Trib2 murine AML model
and 200,000 leukemia cells for the MLL-AF9 murine experiment. For both
experiments a final volume of 200 μl of leukemia cells was injected through the tail
vein. Mice were maintained on Baytril antibiotic in their drinking water pre- and
post-transplantation, for two weeks. Mice were bled via tail vein weekly to test for
disease engraftment; when this was confirmed drug treatment was initiated. For
in vivo studies, CPI0610 (Constellation Pharmaceuticals) was dissolved in heated
0.5% methylcellulose then sonicated (using a Diagneode Bioruptor). RG7112 was
mixed with its vehicle supplied by Roche (2% hydroxypropyl cellulose, 0.1%
polysorbate 80, 0.09% methyl paraben, 0.01% propyl paraben). For the Trib2 fixed
endpoint experiment, Trib2 mice were treated for 21 days. RG7112 was initially
given once daily 100 mg/kg and CPI0610 twice daily 30 mg/kg, both by oral gavage.
However, due to excessive weight loss of one of the combination-treated mice, the
mice received a 2 day “drug holiday” after 10 days and resumed dosing at once
daily RG7112 70 mg/kg and twice daily CPI0610 30 mg/kg. For the Trib2 and
Fig. 5 BRD4 represses p53 target genes. a Total BRD4 peaks determined by ChIP-seq (present in both replicates) in OCI-AML3 cells after indicated drug
treatments (6 h). b Mean total base pairs covered by BRD4 ChIP-seq peaks (peaks present in 2 out of 2 replicates) after the indicated drug treatments of
OCI-AML3 cells. c Genomic distribution of BRD4 binding sites identified by ChIP-seq (peaks present in 2 out of 2 replicates), after the indicated drug
treatments of OCI-AML3 cells. d Heat map showing BRD4 ChIP-seq (peaks present in 2 out of 2 replicates) at 24 p53 target genes, after the indicated drug
treatments of OCI-AML3 cells. e Sequence tracks of representative BRD4 and p53 binding at CDKN1A, after the indicated drug treatments of OCI-AML3
cells. f Sequence tracks of representative BRD4 and p53 binding at BBC3, after the indicated drug treatments of OCI-AML3 cells. g Western blot for BRD4
in OCI-AML3 cells ectopically expressing the short isoform of BRD4 (BRD4S). BRD4L is the long isoform. h qPCR analysis of CDKN1A in OCI-AML3 cells
ectopically expressing BRD4S, in absence or presence of nutlin-3 (***=p≤ 0.001, two-tailed unpaired t-test, Means ± SD are shown, n= 3). i qPCR analysis
of BBC3A in OCI-AML3 cells ectopically expressing BRD4S, in absence or presence of nutlin-3 (***=p≤ 0.001, two-tailed unpaired t-test, Means ± SD are
shown, n= 3).
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MLL-AF9 survival experiments, mice initiated 21 days of drug dosing (not
including 2 drug-free days every 5 days) (RG7112 was given once daily 70 mg/kg
and CPI0610 was given twice daily 30 mg/kg, both by oral gavage). After reaching
the end of treatment, mice were culled immediately or maintained to an ethical
survival endpoint.
Drug treatments of cells in vitro. For drug treatment of primary AML blasts,
2.5 μM nutlin-3 alone, 200 nM CPI203 alone, and the two in combination were
added to triplicate wells to a volume of 100 ul. Control experiments were per-
formed without the addition of drugs using vehicle (DMSO) only. After 48 h cell
viability was measured using the CellTiter-Glo reagent (Promega, G7572), and the
luminescence was detected with Biotek synergy HT plate reader and analyzed using
Gen 5 version 1.08 software. Cell viability was also determined by trypan blue dye
exclusion in some experiments (Sigma, T8154). Apoptosis was assessed used
Annexin V and propidium iodide (PI) staining (BD Biosciences; 556547) as per
manufacturer’s instructions and analyzed using the BD Fortessa flow cytometer.
For p53-promoter based dual GFP/Luminescence assay after 24 h 2.5 μM nultin-3
treatment, cells were lysed using 1xpassive buffer (Promega, E1941) and lysate was
either measured directly for GFP signal or incubated with luciferase assay reagent
LAR (Promega, E1500) for luminescence signal. The GFP and luminescence were
detected with CLARIOstar plate reader and analyzed using Microsoft Excel.
Drug combination and synergy analyses
Chou-Talalay Combination Index method: AML cell lines were treated with
combinations of CPI203 (Constellation Pharmaceuticals) and nutlin-3 (Sigma-
Aldrich, N6287) (CPI203 ranging from 12.5 nM to 800 nM and nutlin-3 ranging
from 1.25 μM to 10 μM) to determine synergistic doses. Cell viability was
determined after 72 h by either trypan blue dye (Sigma, T8154) exclusion or
resazurin (Alamar blue dye, Sigma) with the Envision Fluorescent Reader (Perkin
Elmer). Mean fluorescent values from multiple replicates were calculated for each
condition. Assessment of synergy was made by calculating combination indices
(CI) using Calcusyn software (version 2.0), CI < 1 considered synergistic, CI= 1
considered additive and CI > 1 considered antagonistic25. Bliss Independence
method: AML cell lines were seeded on 384-well plates at 3,000 cells per well and
treated for 72 h (or 24 h for BET PROTAC experiments) with the indicated doses
(2x serial dilution) of drugs, alone or in combination. Luminescence from
quadruplicate was measured using the CellTiter-Glo reagent (Promega, G7572).
Bliss synergy was calculated using SynergyFinder v2.0 web-based application with
default parameters for calculating bliss independence. The difference between the
observed combined effect and the expected combined effect of the two drugs is
called the Excess over Bliss (eob). Positive eob values are indicative of synergistic
interaction, negative eob values are indicative of antagonistic behavior and null eob
values indicate no drug interaction.
RNA extraction, cDNA synthesis, and qPCR. RNA was extracted using the
RNeasy Mini kit (Qiagen, cat no. 7410) according to the manufacturer’s protocol.
On-column DNA digestion was carried out using DNase1 (Qiagen, cat no. 79254).
Eluted RNA was quantified using the Nanodrop 2000 (ThermoFisher Scientific)
and 1 μg RNA was used in cDNA synthesis (Invitrogen, 18080-093), according to
the manufacturer’s instructions. For cDNA synthesis: 1 μg RNA, 1 μl of 50 μM
oligo DT primer (Invitrogen 18418020), 1 μl dNTP mix (10 mM each of dATP,
dGTP, dCTP, and dTTP) and water to a final volume of 14 μl were mixed and
heated at 65 °C for 5 min. After a 1-min incubation on ice, the following were
added: 4 μl 5X first strand buffer, 1 μl 0.1 M DTT, 1 μl Superscript™ Reverse
Transcriptase (Invitrogen, 18080-093), and heated at 25 °C for 5 min. Tubes were
then heated to 55 °C for 1 h and the reaction was inactivated by a 15-min incu-
bation at 70 °C. qPCR was done using 10 μl of SYBR green master mix (2X
DyNAmo HS SYBR green qPCR master mix, Thermo-Scientific, F- 410), 200 nM
of each primer of interest, and water was added to a final volume of 20 μl as a
master mix to 1 μl of DNA in Hard Shell PCR Plates, 96-well white, Bio-Rad,
(HSP9601). The primer sequences used are listed in Supplementary Data 4. The
PCR reactions were performed as follows; 95 °C for 3 min, 95 °C for 10 s, 60 °C for
20 s, 72 °C for 30 s, steps 2 to 4 repeated 39 times, 72 °C for 5 min, and 65 °C for 5 s
then a gradient up to 95 °C for melt curve analysis.
mRNA stability assays. OCI-AML3 cells were treated with Vehicle (DMSO),
200 nM CPI203, 2.5 μM nutlin-3, or the drug combination. After a 2-h incubation,
cells were treated with 5 μM Actinomycin D and harvested after 0, 2, 4, and 6 h of
Actinomycin D treatment. Cell pellets were stored overnight at −80 °C before RNA
was extracted and cDNA synthesized for qPCR analysis as described above.
Abundance of CDKN1A and BBC3 mRNA at each time point was calculated
relative to time 0 using the delta CT method (Ct at time 0 minus Ct of each
time point).
RNA sequencing. Sequencing libraries were made from poly-A RNA, as recom-
mended by Illumina, and sequenced using either an Illumina GAIIX or a NextSeq
500 sequencer. RNA-seq paired-end reads were assessed for quality using the
‘FastQC’ algorithm, trimmed as appropriate using the algorithm ‘trim-galore’
(version 3.0), then aligned to the human genome using the splice-aware aligner
TopHat2. Reference splice junctions were provided by a reference transcriptome
from the Ensembl GRCh37 (hg19) build, release version 73. The Cuffdiff tool from
the Cufflinks suite was used to process aligned reads and perform maximum
likelihood estimation to assess transcript abundances, before calculating the dif-
ferential expression of transcripts across samples. In parallel, aligned reads for
genic isoforms were collated and total read counts per gene were calculated using
htseq-count version 0.5.4p3, before differential expression analysis using the linear
modeling tool DESeq2 was performed. Using both differential expression methods,
significantly changing expression was defined as an FDR-corrected p-value ≤ 0.005.
FPKM (Fragments Per Kilobase of transcript per Million mapped reads) values
were then generated. Gene ontology analysis was performed using Gene Set
enrichment Analysis (GSEA), DAVID (version 6.7) and Ingenuity® Pathway
Analysis (IPA) software.
ChIP-sequencing. ChIP-seq protocol was adapted from previously50,51. Antibody-
bound magnetic beads (anti-rabbit or anti-mouse, as appropriate) (Dynabeads
beads, M280) were incubated with 10 μg of BRD4 antibody (Abcam, 128874) or
10 μg of p53 antibody (Santa Cruz, DO1) (rabbit or mouse IgG was used as a
negative control (Sigma, M7023)) for 4 h at room temperature, then added to the
lysed samples. During the 4-h antibody-bead incubation, 20 × 106 OCI-AML3 cells
were treated with vehicle, 200 nM CPI203, 2.5 μM nutlin-3, or the drug combi-
nation for 6 h. Following this, cells were pelleted at 200 g for 5 min and re-
suspended in serum free RPMI media and cross-linked for 10 min on a rocker by
adding 16% methanol-free paraformaldehyde (Alfa Aesar, 43368) (final con-
centration 1%). Cross-linking was quenched with 2.5 M glycine (final concentra-
tion 0.125 M) for 5 min. Cells were washed twice in cold PBS. Three lysis buffers
(LB1-3) were used to produce chromatin lysates and the following protease inhi-
bitors were added to each: 1x protease inhibitor cocktail (Sigma, P8340) and
50 μg/ml PMSF (Sigma, P7626). In total 10 ml of lysis buffer 1 (LB1) (50 mM
Hepes-KOH, pH 7.5; 140 mM NaCl; 1 mM EDTA; 10% glycerol; 0.5% NP40 and
0.25% Triton X-100) was added to the pellet of cross-linked cells and this was
rocked at 4 °C for 10 min, then centrifuged at 2,000 x g for 4 min at 4 °C. The
supernatant was discarded, and the pellet then re-suspended in 10 ml of LB2
(10 mM Tris-HCl, pH 8.0; 200 nM NaCl; 1 mM EDTA; 0.5 mM EGTA), and
rocked at 4 °C for 5 min. The suspension was again pelleted, the supernatant dis-
carded and the pellet then re-suspended in 2 ml of LB3 (10 mM Tris-HCl, pH 8;
100 mM NaCl; 1 mM EDTA; 0.5 mM EGTA; 0.1% Na-deoxycholate; 0.5% N-
lauroylsarcosine). This 2 ml lysate was transferred to a FACS tube suitable for
sonication. A Soniprep 150 set at 14 microns amplitude was used for 12 cycles of
sonication (each cycle was 30 s on, 60 s off). Sonication was performed one sample
at a time on ice. Following sonication, Triton-X-100 was added to the lysates (final
concentration 1%), and lysates were centrifuged at 16,000 × g for 12 min at 4 °C to
pellet the debris. In total 50 μl of the sonicated lysate from each treatment con-
dition was stored at −20 °C as input control. Cell lysates were pre-cleared with
100 μl of magnetic beads. Following this, the 100 μl of antibody-bead mix was then
added to the cell lysates for overnight immunoprecipitation on a rotating platform
at 4 °C. Following completion of this incubation, the beads were washed 5 times in
1 ml of RIPA buffer (50 mM Hepes-KOH, pH 7.5; 500 mM LiCl; 1 mM EDTA; 1%
NP-40; 0.7% Na deoxycholate plus protease inhibitors as described above). The
pellets were then washed in 1 ml of TBS (20 mM Tris-HCl, pH 7.6; 150 mM NaCl),
centrifuged at 960 x g for 3 min at 4 °C and then, following removal of the
supernatant, the ChIP samples were eluted off the magnetic beads with 200 μl of
elution buffer (50 mM Tris-HCl, pH 8; 10 mM EDTA; 1% SDS) and reverse cross-
linked by heating at 65 °C for 6–18 h. The beads were vortexed every 5 min for the
first 15 min. A total of 200 μl of TE was added to each IP and Input samples. 8 μl of
1 mg/ml RNaseA (Ambion, 2271) was added and the samples incubated at 37 °C
for 30 min. A total of 4 μl of proteinase K (20 mg/ml) (Invitrogen, 25530-049) was
then added and the samples incubated at 55 °C for 1–2 h. The samples were then
purified using the Qiagen MinElute PCR purification kit (28006), eluted in 30 μl
elution buffer, and stored at −20 °C until required for qPCR or sequencing.
ChIP-seq libraries were made as recommended by Illumina, using the NEBNext
Ultra DNA Lib Prep kit (E7370S) and NEBNext Multiplex Oligos, (Index Primers
Set 2; E7500S). The quality of the libraries was assessed using the Agilent 2200 tape
station (Agilent Technologies), with the Agilent D1000 ScreenTape system
(Agilent, 5067-5582) and D1000 reagents (Agilent, 5067-5583). Sequencing was
performed on an Illumina NextSeq 500 sequencer using the High Output kit v2 to
perform 75 cycles of single-read sequencing.
Sequenced single-end ChIP-seq reads were trimmed using trim-galore (version
3.0) and aligned to the hg19 build of the human genome using Bowtie2 alignment
software. Reads with a Phred quality score of <15 were removed. Non-unique or
duplicate reads were removed using samtools and Picard tools (v1.98) respectively.
Regions of BRD4 occupancy were determined using the SICER algorithm with a
redundancy threshold of 1, a window size of 200, a fragment size of 150, an
effective genome fraction of 0.75, a gap size of 200 and an FDR corrected p-value of
0.01 (suited to broader BRD4 peaks). To reduce experimental bias, a robust peak
set, defined as being present in both replicates using the bedtools intersect function,
was used. Regions of p53 occupancy were determined using the Macs tool (version
1.4) with a p-value cutoff of 1e-5 (suited to narrower peaks), then robust peaks that
were present in at least 2 replicates were identified using the bedtools intersect
function. BRD4 and p53 peaks were visualized using either the UCSC web interface
or the WashU browser.
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Ectopic expression and gene knockdown by shRNA or CRISPR. Gene knock-
down or overexpression in OCI-AML3 cells was achieved by viral transfection. DNA
constructs were used to generate virus for infection of OCI-AML3 cells to generate
knock-down or over expression (pTRIPZ and pLKO.1 for knock-down, pLenti-
CRISPR V2 for CRISPR knock-out, and pLenti4 and pCDH for over expression
(Supplementary Data 5)). To generate virus, 2 × 106 HEK-293T (ATCC, CRL-11268)
or HEK 293FT (gifted from Dr David Bryant, Beatson Institute for CRUK) were
plated one day prior to transfection at 2 million cells per plasmid in a 10 cm plate in
culturing media (DMEM with 10% v/v FBS and L-glutamine 2mM and penicillin
streptomycin 100 units per ml). Transfection was carried out in antibiotic-free
culturing media (6ml) using 10 μl lipofectamine (Lipofectamine ® 2000Reagent,
1 mg/ml, Invitrogen P/N 2887) in 400 μl Opti-mem media (Gibco Opti-mem reduced
serum media, Life Technologies 31985062). This was combined with a further 400 μl
Opti-mem containing 2.5 μg of plasmid DNA, 1.86 μg of ps PAX2 and 1 μg of VSVG,
incubated for 20–25min at room temperature, and then added dropwise onto the
target plate of HEK-293T. After 6 h the medium was aspirated and re-freshed with
6mls of normal culture medium containing antibiotics as above. Two days after
transfection of the HEK-293T, infection of the target cells was initiated by spinning
down 1.5 × 106 target cells per sample and re-suspending in 400 μl of culture media in
a 12-well plate. 6 ml of virus-containing media was removed from the plate of 293
T cells (the 293 T cells were refreshed with 6mls of antibiotic-containing media to
allow a second infection the following day), filtered through a 0.45 μM filter and
mixed with polybrene (8 μg/ml (Millipore TR-1003). To each well of target cells, 1 ml
of virus-containing media was added. A GFP-expressing virus and a ‘cells only’ well
were included as controls for the transfection and infection respectively. The 12-well
plate was then spun at 2500 rpm at room temperature for 90mins and incubated at
37 °C for 3–6 h. Cells were then transferred to a 25 cm flask with 9mls of media for an
overnight incubation. The following day a second infection was carried out as
described above, and 24 h after this the cells were selected with 1 μg/ml puromycin.
Immunoblotting and antibodies. Cells were lysed directly in 1x Laemmli sample
buffer (2% SDS, 10% glycerol, 0.01% bromophenol blue, 62.5 mM Tris, pH 6.8) and
boiled for 4min. A total of 30 μg of protein was loaded into each lane of the gel. The
polyacrylamide gels (BioLegend 456-1095 or NOVEX) were run at 150V in 1x
running buffer (25mM Tris, 192mM glycine, 0.1% SDS, pH8.3). Proteins were
transferred onto PVDF membranes in transfer buffer (20% methanol, 25mM Tris,
192mM glycine, 0.01% SDS, 20%) for 1 h 25min at 60V at room temperature.
Membranes were dried on top of filter paper and reactivated with methanol, blocked
in TBS with 5% milk or 4% BSA and probed with antibodies overnight at 4 °C. β-
Actin was used as a loading control for all western blots (1 in 200,000 dilution, Sigma
A1978). All antibodies were diluted in 5% BSA TBS pH 7.5 with 0.05% sodium azide.
Primary antibodies to the following targets were used at 0.1–1 μg/ml: Actin (Sigma,
A1978, RRID:AB_476692), CDKN1A (Santa Cruz, 397, RRID:AB_632126), c-MYC
(Santa Cruz, 764, RRID:AB_631276), MDM2 (Santa Cruz, 965, RRID:AB_627920),
PARP (Cell Signalling, 9542, RRID:AB_2160739), BBC3 (Imgenex, 458, RRID:
AB_1151450), TP53 (DO1) (Santa Cruz, 126, RRID:AB_628082), NOXA (Abcam,
13654, RRID:AB_300536), BRD4 (Abcam, 128874, RRID:AB_11145462), BCL-2 (Cell
signaling, 2870, RRID:AB_2290370) (Supplementary Data 6). The following morning
membranes were washed in TBS pH 7.5 (3 ×5min washes) and then incubated with
species-matched HRP-linked secondary antibody. The following secondary antibodies
were added for a 1-h incubation at room temperature: anti-mouse IgG HRP-linked
(Dako, p0447) and anti-rabbit IgG HRP-linked (Cell signaling, 7074 s), both at a
dilution of 1:5,000. Following incubation with secondary antibodies, membranes were
given 3 ×10-min washes in TBS pH7.5+ 0.1%Tween 20 and then incubated in ECL
Western blotting chemiluminescent substrate (Thermo Scientific, 32106) for 1 min.
Visualisation of protein bands was then carried out using either GE Healthcare
Amersham hyperfilm on a Kodak X-Omat 480 RA X-ray processor, or BIORAD
ChemiDoc Imaging system. All experiments were performed multiple times and
confirmed to be reproducible.
FACS analysis. For flow cytometric evaluation of apoptosis in AML cell lines and
primary murine AML cells treated with the above single agents or combination
treatments, apoptosis was measured by combined Annexin-V/propidium iodide
(PI) staining (Cambridge Bioscience, K101-400), myeloid differentiation was
assessed using stains for CD11b (eBioscience, 12-0081) and GR1 (eBioscience, 25-
5931), lymphoid differentiation was assessed using stains for CD4 (Biolegend,
100553), CD8a (eBioscience, 12-0081), CD19 (eBioscience, 47-0193080) and B220
(eBioScience, 45-0452). Drug or vehicle-treated cells were collected and first
washed with 1 ml of PBS. Cells were then re-suspended in 1 ml of 1× Binding
Buffer. Following this, the relevant stain of interest was added and samples incu-
bated for 10 min at room temperature in the dark. Samples of human cell lines
were then analyzed on a FACSCalibur (BD Biosciences) and primary murine
samples were analyzed on a FACSCanto (BD Bioscience). Cells were centrifuged at
1000 rpm for 5 min and resuspended in 1 ml sorting buffer (PBS 2 % FBS) and
DAPI was added immediately prior to sort (final concentration 1 μg/ml; 1 in 1000
dilution). Cells were sorted by Jennifer Cassells at the Paul O’ Gorman Leukaemia
Research Centre using a BD FACSARIA III sorter and were collected in 1 ml
sorting buffer, pooled, centrifuged as above and left to recover in culturing medium
at 37 °C. Gating strategy for sorting GFP Positive cells was live cells>cell profi-
le>single cells>GFP positive cells.
For assessment of disease engraftment and disease burden in mice, blood was
collected via tail vein. Red blood cell lysis was carried out using BioLegend 10x red
blood cell lysis buffer as per manufacturers’ instructions (incubation time was
increased to 8min after optimization). After centrifugation, cell pellets were
resuspended in 400 μl PBS and % GFP+ was measured using the BD Fortessa flow
cytometer. At mouse cull, leg bones were cleaned upon removal then crushed using a
pestle and mortar. The cell suspension was filtered and washed with ice-cold PBS+
2% FBS. For spleen and thymus, the organ was placed in a 70 μM cell strainer and
pushed through using the plunger of a 5ml syringe into a 50ml falcon containing
PBS+ 2% FBS. Suspensions were pelleted at 200 g for 5min, and the pellets
resuspended in red cell lysis buffer before being pelleted as above. Finally, cells were
washed in 1ml PBS+ 2% FBS. For FACS, compensation was calculated using
ULTRACOMP beads (E biosciences 01-2222-41) incubated for 20min with each
antibody used in the experiment. Fluorescence minus one (FMO) controls were also
included using cells incubated with a mix of all antibodies except one in each FMO
control. A master mix was prepared containing all antibodies at a 1 in 250 dilution
(myeloid cells [CD11b, E- bioscience, 17-0112-83; Gr1, E- bioscience, 25-5931-81], B
cells [B220, E- bioscience, 45-0452-80; CD19, E- bioscience, 47-0193080], T cells
[CD4, Biolegend, 100547; CD8, E- bioscience, 12-0081-82] (Supplementary Data 6))
in PBS+ 2% FBS and cell pellets were re-suspended in 50 μl of master mix for a 30
min incubation on ice and away from light. Immediately prior to FACS analysis DAPI
was added at a 1 in 1000 dilution (1 μg/ml) (Sigma, D9542-1MG).
Statistical analysis. Results were statistically analyzed in GraphPad Prism (ver-
sion 7.0, GraphPad Software Inc., San Diego, CA) and presented as mean±SEM.
Statistically significant differences between two groups were assessed by two-tailed
unpaired t-test. p ≤ 0.05 was considered significant. ns, not significant; *p ≤ 0.05;
**p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 for indicated comparisons. Statistical
details of each experiment can be found in the Results and Figure Legend sections.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this paper.
Data availability
Source Data Files are available in the Supplementary Data as an excel file with each sheet
being a separate figure: “Figure Data.xls”. For Figures with associated raw data, see the
Supplementary Dataset File. Chip Seq and RNA seq data has been deposited in the Gene
Expression Omnibus (GEO) under accession codes GSE132246, GSE132247, GSE132244,
and GSE 132245. All other data supporting the findings of this study are available from
the corresponding author upon reasonable request. Links to GEO accession are below
(Supplementary Data 7): https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE132244, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132245,
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132246, https://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE132247. Source data are provided with this paper.
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